Antioxidant supplements fail to improve sperm quality in infertile men

July 02, 2018

Barcelona, 2 July 2018: Despite many study results suggesting that antioxidants have a positive effect on abnormal sperm parameters associated with male infertility, a large US clinical trial of 174 couples has found that an antioxidant formulation taken daily by the male partner for a minimum of three months made no difference to sperm concentration, motility or morphology, nor to the rate of DNA fragmentation.

Results of the study, which was performed in eight American fertility centres with the support of the National Institutes of Health, are presented today at the 34th Annual Meeting of ESHRE by Professor Anne Steiner from the University of North Carolina at Chapel Hill, USA.

All men in the study had been diagnosed with male factor infertility, reflected in sub-normal levels of sperm concentration, motility, or morphology, or higher than normal rates of DNA fragmentation.(1) These sperm parameters were measured at the start of the trial and at three months. In between, the men allocated to the antioxidant intervention were given a daily supplement (in tablet form) containing vitamins C, D3 and E, folic acid, zinc, selenium and L-carnitine; the control group received a placebo.

At three months, results showed only a "slight" overall difference in sperm concentration between the two groups, and no significant differences in morphology, motility, or DNA fragmentation measurements. Sub-group analysis (according to different types of sperm abnormality) found no significant differences in sperm concentration (in oligospermic men), motility (in asthenospermic men), and morphology (in teratospermic men).(1) There was also no change seen after three months in men with high rates of DNA fragmentation (28.9% in the antioxidant group and 28.8 in the placebo group).(2)

A further endpoint of the trial was natural conception during the initial three month study period, but this too did not differ between the two groups of the entire cohort - a pregnancy rate of 10.5% in the antioxidant group and 9.1% in the placebo. These rates were also comparable at six months (after continued antioxidant or placebo for the male partner and three cycles of clomiphene and intrauterine insemination for the female partner).

As background to the trial, the authors explain that many of the previous studies in which antioxidants have been linked to improvements in sperm quality have been limited by small numbers, heterogeneity in patients, variety of antioxidant, and non-clinical endpoints. This study, therefore, was designed to close these gaps in knowledge and provide a stronger evidence base.(3)

In commenting on this randomised controlled trial, Steiner said it was one of the largest of its kind with a "well characterised" study population. Explaining the three-month study period, she said that spermatogenesis and transport together take approximately 74 days, but that reactive oxygen species have a greater negative effect during the much shorter sperm transport phase rather than during spermatogenesis; thus, antioxidants are thought to have benefit even after a short interval.

As a result and based on findings from this large clinical trial, Steiner and her colleagues now conclude that "the results do not support the empiric use of antioxidant therapy for male factor infertility in couples trying to conceive naturally".
-end-
Abstract O-064, Monday 2 July 2018

Antioxidants in the treatment of male factor infertility: Results from the double blind, multi-center, randomized controlled Males, Antioxidants, and Infertility (MOXI) trial

Notes

1. WHO-defined standard values of semen parameters are as follow: sperm concentration equal to or greater than 15 million per milliliter, motility of 32% or higher, and normal morphology equal or more than 4%. In this study men with sperm concentration 15 million/ml or less, motility of 40% or less, normal morphology of 4% or less, and DNA fragmentation of 25% or more were eligible. Defects in sperm functions include oligospermia (low sperm count), azoospermia (absence of any sperm cells), teratospermia (high levels of abnormal morphology), as thenospermia (high levels of reduced sperm motility).

2. Natural antioxidants, including vitamins C and E, are found in semen ostensibly as protection against the activity of free radicals and oxidative stress. Several studies have shown that antioxidant levels are lower in the semen of infertile than in fertile men - which thus explains the rationale for antioxidant supplementation. DNA fragmentation is a measure of structural defects of sperm cells. Again, oxidative stress in the form of reactive oxygen species has been implicated in their interaction with DNA to cause strand breaks and fragmentation. Results are usually presented as the percentage of cells having fragmented DNA.

3. A Cochrane review of 48 trials found modest improvements in pregnancy and live birth rates in couples where the men took antioxidant supplements (prior to IVF), but the quality of the evidence was described as "low" (see Showell MG, Mackenzie-Proctor R, Brown J, et al. Antioxidants for male subfertility. Cochrane Database 2014; doi CD007411.pub3).

* When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.

For further information on the details of this press release, contact:

Christine Bauquis at ESHRE
Mobile: +32 (0)499 25 80 46
Email: christine@eshre.eu

European Society of Human Reproduction and Embryology

Related Clinical Trial Articles from Brightsurf:

Clinical trial investigates gabapentin for alcohol use disorder
This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

Electrical stimulation helps treat constipation in clinical trial
Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

Read More: Clinical Trial News and Clinical Trial Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.